Skip to content
Recall Observatory FDA recall evidence

Drug product

Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ

D-0190-2025

December 30, 2024

Class II

Product summary

Firm
Rising Pharma Holding, Inc.
Event
Event 96074
Status
Ongoing
Classification
Class II
Quantity
244,460 bottles
Official record key
drug-enforcement:D-0190-2025

Official wording

Reason: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Code information: Lot # a) DT6023053A, DT6023061A, DT6023068A, DT6023074A, exp. date Jan-25; DT6023078A, DT6023076A, exp. date Feb-25; DTC24043A, DTC24044A, exp. date Dec-25 b) DT6023002A, DT6023016A, DT6023036A, exp. date Dec-24; DT6023048A, exp. date Jan-25

Distribution pattern: Nationwide

Derived failure modes

  • Foreign material or chemical contamination

    reason.foreign_material_chemical_contamination · v1.0.0

    N-nitroso-duloxetine impurity
  • Manufacturing or process control

    reason.manufacturing_process_control · v1.0.0

    CGMP Deviations